Plethora Solutions Holdings Plc Regulatory News (PLE)

22 Aug 2006 07:01

Plethora Solutions Holdings PLC22 August 2006 22nd August 2006 New Appointment Sandrine Cailleteau Appointed as Chief Business Officer Plethora Solutions Holdings PLC ("Plethora" or the "Company", AIM: PLE), thespecialist developer of products for the treatment and management of urologicaldisorders is pleased to announce that it has appointed Sandrine Cailleteau asChief Business Officer (CBO). Sandrine joins Plethora as a number of itsclinical development programmes are moving through Phase II clinical studiesfrom where they will be licensed to development and marketing partners. Sandrine Cailleteau brings more than 15 years experience in strategic planningand licensing and joins Plethora Solutions from Laboratoires Fournier where shewas Head of Global Business Development and Licensing. Before joiningLaboratoires Fournier in November 2002 she was Director Strategic Planning andPartnerships of Hesperion, now part of Cerep. Prior to that, she spent 10 yearswith Sanofi, and then Sanofi-Synthelabo in different positions, the latest beingLicensing Project Director at Paris headquarters. Her other roles at Sanofiincluded Manager Investor Relations, M&A and Strategic Planning Manager whereshe was responsible for both acquisitions and divestitures, and then PublicAffairs (where she spent 3 years in Washington DC, representing Sanofi withInternational Organizations and notably the World Bank). Dr. Steven Powell, Chief Executive Officer, welcoming her to the team, said: "Sandrine brings the experience, strategic vision and commitment to help driveall aspects of our business forward. Her proven licensing experience andextensive involvement in strategic transactions will enable Plethora to continueto grow its business and build on its growing reputation as a leading productdevelopment and marketing company specialising in urology." Sandrine Cailleteau commented: "I am delighted to be joining Plethora at this exciting time, as the company isextending its portfolio further while establishing additional strategiccollaborations. I look forward to working with the team to drive theseinitiatives." -Ends- For further information contact: Plethora Solutions Tel : 020 7269 8630Steven Powell City/Financial Enquiries Tel: 020 7379 5151MaitlandBrian Hudspith/Liz Morley/Wendy Timmons Scientific/Trade Press Enquiries Tel: 020 7861 3838DeFacto CommunicationsRichard Anderson About Plethora: Plethora is focused on the development of products for the treatment ofurological disorders. The Company has products in clinical development for thetreatment of overactive bladder, benign prostatic hyperplasia, stress urinaryincontinence, interstitial cystitis and premature ejaculation. In January 2006,Plethora acquired Minneapolis (Mn) based Timm Medical Technologies Inc whichmarkets products for the treatment of erectile dysfunction (ED) to urologyclinics through a US-based speciality sales team. The Company is headquarteredin the UK and is listed on the London Stock Exchange (AIM:PLE) Furtherinformation is available at www.plethorasolutions.co.uk This information is provided by RNS The company news service from the London Stock Exchange